دورية أكاديمية
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
| العنوان: | A randomized, controlled trial of 3.0 mg of liraglutide in weight management |
|---|---|
| المؤلفون: | Pi Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David C. W., Le Roux, Carel W., Ortiz, Rafael Violante, Jensen, Christine Bjørn, Wilding, John P. H., the SCALE Obesity, Prediabetes NN8022 1839 Study Group . . ., . ., MARCHESINI REGGIANI, GIULIO |
| المساهمون: | Pi-Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David C.W., Le Roux, Carel W., Ortiz, Rafael Violante, Jensen, Christine Bjørn, Wilding, John P.H., the SCALE Obesity and Prediabetes NN8022-1839 Study Group ., Marchesini, Giulio |
| سنة النشر: | 2015 |
| المجموعة: | IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| مصطلحات موضوعية: | Adult, Blood Glucose, Body Mass Index, Combined Modality Therapy, Counseling, Diarrhea, Diet, Reducing, Double-Blind Method, Exercise, Female, Glucagon-Like Peptide 1, Human, Hypoglycemic Agent, Injections, Subcutaneou, Liraglutide, Male, Middle Aged, Nausea, Obesity, Weight Lo, Medicine (all) |
| الوصف: | BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight. RESULTS: At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes. At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P<0.001, with last-observation-carried-forward imputation). A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P<0.001). The most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea. Serious events occurred in 6.2% of the patients in the liraglutide group and in 5.0% of the patients in the placebo group. CONCLUSIONS: In this study, 3.0 mg of liraglutide, as an ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/26132939; info:eu-repo/semantics/altIdentifier/wos/WOS:000357218700004; volume:373; issue:1; firstpage:11; lastpage:22; numberofpages:12; journal:NEW ENGLAND JOURNAL OF MEDICINE; http://hdl.handle.net/11585/525492Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84936166069 |
| DOI: | 10.1056/NEJMoa1411892 |
| الإتاحة: | https://doi.org/10.1056/NEJMoa1411892Test http://hdl.handle.net/11585/525492Test |
| رقم الانضمام: | edsbas.9811ECF4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1056/NEJMoa1411892 |
|---|